Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

by B2i | Feb 23, 2023 | Press Releases

ROCKVILLE, Md., Feb. 23, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it...

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31

by B2i | Jan 26, 2023 | Press Releases

ROCKVILLE, Md., Jan. 26, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

by B2i | Jan 17, 2023 | Press Releases

ROCKVILLE, Md., Jan. 17, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

by B2i | Jan 12, 2023 | Press Releases

ROCKVILLE, Md., Jan. 12, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...

Shuttle Pharmaceuticals Manuscript Published in Clinical Cancer Research

by B2i | Jan 10, 2023 | Press Releases

ROCKVILLE, Md., Jan. 10, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...